As part of its broader strategy to expand specialty participation in value-based care, the Centers for Medicare and Medicaid Services (CMS) has finalized a mandatory five-year Ambulatory Specialty ...
Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...
Chronic consumption of high levels of caffeine a day can lead to an increase in high heart rate and blood pressure that persists after resting from a step test, increasing the risk of cardiovascular ...
Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...
Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...
Studies in all JACC journals are embargoed until they are published online. The chart below details the general embargo time and day for each journal; however, these dates are subject to change and ...
A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure (SBP) by between ...
Until about 15 years ago, most cardiologists were found in private practices, where the physicians – usually in groups – owned the practice and had privileges for hospital-based services at one or ...
The following are key points from the 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency ...
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...
The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...
The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results